PepsiCo Faces Pressure to Meet Elliott Targets Amid GLP-1 Weight-Loss Drug Threat
· Business · Reuters, MIT Tech Review
PepsiCo is running out of time to achieve performance targets proposed by activist investor Elliott Management while navigating headwinds from rising GLP-1 weight-loss drugs. The snack and beverage giant faces shifting consumer dietary habits as popular appetite-suppressing medications alter global food demand. Investors are closely monitoring the company's strategic adjustments to protect profit margins and core product portfolios in key international markets. The report does not specify the exact deadline set by Elliott Management for reaching the restructuring goals. PepsiCo executives have not announced any major portfolio divestitures in response to the shareholder pressure.
Why it matters
The rise of GLP-1 drugs poses a fundamental challenge to traditional packaged-food giants, forcing major shifts in global product formulations.
Read the original report — Reuters
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.